Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab

Marta Casal Moura, Alvise Berti, Karina A. Keogh, Gerald W. Volcheck, Ulrich Specks, Misbah Baqir

Research output: Contribution to journalArticle

Abstract

Objectives: Rituximab (RTX) treatment is used for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, but its benefits in eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. Our aim was to characterize asthma control and glucocorticoid (GC) sparing after RTX treatment. Methods: A retrospective, computer-assisted search was performed to identify patients with EGPA and GC-dependent asthma diagnosed between 2000 and 2017 who received RTX for remission induction. Demographic and clinical features were analyzed. Results: Of the 17 patients included, the majority were myeloperoxidase-ANCA positive (n = 13, 76.5%). Uncontrolled asthma symptoms and atopy were present in 13 patients (76.5%). RTX was used for initial remission induction in patients with new onset of severe disease (n = 5, 29.4%) and after failed remission induction with other immunosuppression (n = 12, 70.6%). It was used for remission maintenance in nine patients (52.9%). GCs were used for maintenance at a median dose of 25 mg/day (interquartile range, 16.25–37.5). At the end of follow-up, 13 patients (76.5%) had non-severe or controlled asthma, and remission was achieved in 12 (70.6%). Median serum eosinophil and C-reactive protein values decreased (1.06 vs 0.10 × 109/L [P =.012] and 27.0 vs 5.0 mg/dL [P =.001], respectively), whereas pulmonary function test results remained unchanged. Median GC dose was significantly reduced at 6, 12, 18, and 24 months (P <.0001). Patients receiving RTX for maintenance required less than 10 mg of GCs for asthma control. Conclusion: RTX seems to be safe and have GC-sparing efficacy for asthma control in EGPA. Randomized controlled trials are needed for detailed study of RTX for treating EGPA.Key Points• In this retrospective study we have concluded that rituximab (RTX) might be considered for the control of severe corticosteroid-dependent asthma in eosinophilic granulomatosis polyangiitis (EGPA) patients especially when myeloperoxidase antibodies are positive.• Rituximab has not been studied particularly for asthma control in EGPA patients.• The most noticeable effect of RTX was the decrease in the use of corticosteroids for the control of asthma.

Original languageEnglish (US)
JournalClinical rheumatology
DOIs
StateAccepted/In press - Jan 1 2020

Fingerprint

Granulomatosis with Polyangiitis
Asthma
Remission Induction
Glucocorticoids
Antineutrophil Cytoplasmic Antibodies
Maintenance
Peroxidase
Adrenal Cortex Hormones
Rituximab
Respiratory Function Tests
Vasculitis
Eosinophils
C-Reactive Protein
Immunosuppression
Randomized Controlled Trials
Retrospective Studies
Demography

Keywords

  • Autoantibodies
  • Churg-Strauss syndrome
  • Eosinophilic granulomatosis with polyangiitis
  • Epidemiology
  • Observational studies
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. / Casal Moura, Marta; Berti, Alvise; Keogh, Karina A.; Volcheck, Gerald W.; Specks, Ulrich; Baqir, Misbah.

In: Clinical rheumatology, 01.01.2020.

Research output: Contribution to journalArticle

Casal Moura, Marta ; Berti, Alvise ; Keogh, Karina A. ; Volcheck, Gerald W. ; Specks, Ulrich ; Baqir, Misbah. / Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. In: Clinical rheumatology. 2020.
@article{310351f332d146e5a497a94936f254b2,
title = "Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab",
abstract = "Objectives: Rituximab (RTX) treatment is used for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, but its benefits in eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. Our aim was to characterize asthma control and glucocorticoid (GC) sparing after RTX treatment. Methods: A retrospective, computer-assisted search was performed to identify patients with EGPA and GC-dependent asthma diagnosed between 2000 and 2017 who received RTX for remission induction. Demographic and clinical features were analyzed. Results: Of the 17 patients included, the majority were myeloperoxidase-ANCA positive (n = 13, 76.5{\%}). Uncontrolled asthma symptoms and atopy were present in 13 patients (76.5{\%}). RTX was used for initial remission induction in patients with new onset of severe disease (n = 5, 29.4{\%}) and after failed remission induction with other immunosuppression (n = 12, 70.6{\%}). It was used for remission maintenance in nine patients (52.9{\%}). GCs were used for maintenance at a median dose of 25 mg/day (interquartile range, 16.25–37.5). At the end of follow-up, 13 patients (76.5{\%}) had non-severe or controlled asthma, and remission was achieved in 12 (70.6{\%}). Median serum eosinophil and C-reactive protein values decreased (1.06 vs 0.10 × 109/L [P =.012] and 27.0 vs 5.0 mg/dL [P =.001], respectively), whereas pulmonary function test results remained unchanged. Median GC dose was significantly reduced at 6, 12, 18, and 24 months (P <.0001). Patients receiving RTX for maintenance required less than 10 mg of GCs for asthma control. Conclusion: RTX seems to be safe and have GC-sparing efficacy for asthma control in EGPA. Randomized controlled trials are needed for detailed study of RTX for treating EGPA.Key Points• In this retrospective study we have concluded that rituximab (RTX) might be considered for the control of severe corticosteroid-dependent asthma in eosinophilic granulomatosis polyangiitis (EGPA) patients especially when myeloperoxidase antibodies are positive.• Rituximab has not been studied particularly for asthma control in EGPA patients.• The most noticeable effect of RTX was the decrease in the use of corticosteroids for the control of asthma.",
keywords = "Autoantibodies, Churg-Strauss syndrome, Eosinophilic granulomatosis with polyangiitis, Epidemiology, Observational studies, Vasculitis",
author = "{Casal Moura}, Marta and Alvise Berti and Keogh, {Karina A.} and Volcheck, {Gerald W.} and Ulrich Specks and Misbah Baqir",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/s10067-019-04891-w",
language = "English (US)",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",

}

TY - JOUR

T1 - Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab

AU - Casal Moura, Marta

AU - Berti, Alvise

AU - Keogh, Karina A.

AU - Volcheck, Gerald W.

AU - Specks, Ulrich

AU - Baqir, Misbah

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Objectives: Rituximab (RTX) treatment is used for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, but its benefits in eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. Our aim was to characterize asthma control and glucocorticoid (GC) sparing after RTX treatment. Methods: A retrospective, computer-assisted search was performed to identify patients with EGPA and GC-dependent asthma diagnosed between 2000 and 2017 who received RTX for remission induction. Demographic and clinical features were analyzed. Results: Of the 17 patients included, the majority were myeloperoxidase-ANCA positive (n = 13, 76.5%). Uncontrolled asthma symptoms and atopy were present in 13 patients (76.5%). RTX was used for initial remission induction in patients with new onset of severe disease (n = 5, 29.4%) and after failed remission induction with other immunosuppression (n = 12, 70.6%). It was used for remission maintenance in nine patients (52.9%). GCs were used for maintenance at a median dose of 25 mg/day (interquartile range, 16.25–37.5). At the end of follow-up, 13 patients (76.5%) had non-severe or controlled asthma, and remission was achieved in 12 (70.6%). Median serum eosinophil and C-reactive protein values decreased (1.06 vs 0.10 × 109/L [P =.012] and 27.0 vs 5.0 mg/dL [P =.001], respectively), whereas pulmonary function test results remained unchanged. Median GC dose was significantly reduced at 6, 12, 18, and 24 months (P <.0001). Patients receiving RTX for maintenance required less than 10 mg of GCs for asthma control. Conclusion: RTX seems to be safe and have GC-sparing efficacy for asthma control in EGPA. Randomized controlled trials are needed for detailed study of RTX for treating EGPA.Key Points• In this retrospective study we have concluded that rituximab (RTX) might be considered for the control of severe corticosteroid-dependent asthma in eosinophilic granulomatosis polyangiitis (EGPA) patients especially when myeloperoxidase antibodies are positive.• Rituximab has not been studied particularly for asthma control in EGPA patients.• The most noticeable effect of RTX was the decrease in the use of corticosteroids for the control of asthma.

AB - Objectives: Rituximab (RTX) treatment is used for antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis, but its benefits in eosinophilic granulomatosis with polyangiitis (EGPA) are unclear. Our aim was to characterize asthma control and glucocorticoid (GC) sparing after RTX treatment. Methods: A retrospective, computer-assisted search was performed to identify patients with EGPA and GC-dependent asthma diagnosed between 2000 and 2017 who received RTX for remission induction. Demographic and clinical features were analyzed. Results: Of the 17 patients included, the majority were myeloperoxidase-ANCA positive (n = 13, 76.5%). Uncontrolled asthma symptoms and atopy were present in 13 patients (76.5%). RTX was used for initial remission induction in patients with new onset of severe disease (n = 5, 29.4%) and after failed remission induction with other immunosuppression (n = 12, 70.6%). It was used for remission maintenance in nine patients (52.9%). GCs were used for maintenance at a median dose of 25 mg/day (interquartile range, 16.25–37.5). At the end of follow-up, 13 patients (76.5%) had non-severe or controlled asthma, and remission was achieved in 12 (70.6%). Median serum eosinophil and C-reactive protein values decreased (1.06 vs 0.10 × 109/L [P =.012] and 27.0 vs 5.0 mg/dL [P =.001], respectively), whereas pulmonary function test results remained unchanged. Median GC dose was significantly reduced at 6, 12, 18, and 24 months (P <.0001). Patients receiving RTX for maintenance required less than 10 mg of GCs for asthma control. Conclusion: RTX seems to be safe and have GC-sparing efficacy for asthma control in EGPA. Randomized controlled trials are needed for detailed study of RTX for treating EGPA.Key Points• In this retrospective study we have concluded that rituximab (RTX) might be considered for the control of severe corticosteroid-dependent asthma in eosinophilic granulomatosis polyangiitis (EGPA) patients especially when myeloperoxidase antibodies are positive.• Rituximab has not been studied particularly for asthma control in EGPA patients.• The most noticeable effect of RTX was the decrease in the use of corticosteroids for the control of asthma.

KW - Autoantibodies

KW - Churg-Strauss syndrome

KW - Eosinophilic granulomatosis with polyangiitis

KW - Epidemiology

KW - Observational studies

KW - Vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85077284145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077284145&partnerID=8YFLogxK

U2 - 10.1007/s10067-019-04891-w

DO - 10.1007/s10067-019-04891-w

M3 - Article

AN - SCOPUS:85077284145

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

ER -